The Role of Tiopronin for the Prevention of Chemotherapy-Related Liver Toxicity in Advanced Colorectal Cancer Patients Treated with mFOLFOX7: A Prospective Analysis

2014 ◽  
Vol 100 (4) ◽  
pp. 446-451 ◽  
Author(s):  
Xiao-peng Li ◽  
Feng Wen ◽  
Wu Yang ◽  
Yi-bo Deng ◽  
Meng Li ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Advanced Colorectal Cancer ◽  
Liver Toxicity ◽  
Prospective Analysis ◽  
Colorectal Cancer Patients

The Role of 5-Fluorouracil (5-FU) Reintroduction with Irinotecan or Oxaliplatin in Truly 5-FU-Refractory Advanced Colorectal Cancer Patients

Oncology ◽  
2005 ◽  
Vol 68 (2-3) ◽  
pp. 212-216 ◽  
Author(s):  
M. Scartozzi ◽  
A. Sobrero ◽  
G. Gasparini ◽  
R. Berardi ◽  
V. Catalano ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Advanced Colorectal Cancer ◽  
Colorectal Cancer Patients

scholarly journals The Role of HER‐3 Expression in the Prediction of Clinical Outcome for Advanced Colorectal Cancer Patients Receiving Irinotecan and Cetuximab

2011 ◽  
Vol 16 (1) ◽  
pp. 53-60 ◽  
Author(s):  
Mario Scartozzi ◽  
Alessandra Mandolesi ◽  
Riccardo Giampieri ◽  
Alessandro Bittoni ◽  
Chiara Pierantoni ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Outcome ◽  
Cancer Patients ◽  
Advanced Colorectal Cancer ◽  
Colorectal Cancer Patients

The new era in the treatment of advanced colorectal cancer patients: the role of monoclonal antibodies

2006 ◽  
Vol 11 (4) ◽  
pp. 665-683 ◽  
Author(s):  
Bruno Vincenzi ◽  
Gaia Schiavon ◽  
Marianna Silletta ◽  
Daniele Santini ◽  
Giuseppe Tonini
Keyword(s):  
Colorectal Cancer ◽  
Monoclonal Antibodies ◽  
Cancer Patients ◽  
Advanced Colorectal Cancer ◽  
New Era ◽  
Colorectal Cancer Patients

scholarly journals Predictive Value of UGT1A1 Polymorphisms in Irinotecan-Induced Toxicity and Therapeutic Efficacy in Colorectal Cancer Patients

2020 ◽  
Vol 4 (2) ◽  
pp. 39-46
Author(s):  
Qianqian Yu ◽  
Zhihuan Li ◽  
Xiaoqi Nie ◽  
Lu Wang ◽  
Chen Gong ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Metabolic Pathways ◽  
Therapeutic Efficacy ◽  
Advanced Colorectal Cancer ◽  
Inactive Form ◽  
Predictive Role ◽  
Colorectal Cancer Patients ◽  
The Impact

Irinotecan-based chemotherapy is a fundamental cytotoxic regimen for advanced colorectal cancer. The disposition of irinotecan is known to vary in a fashion partially depending on genetic variations in the drug metabolic pathways. UDP-glucuronosyltransferase (UGT)1A1 is a predominant enzyme that converts the active metabolite of irinotecan to the inactive form via a glucuronidation process. Several UGT1A1 polymorphisms are linked to SN-38 glucuronidation and irinotecan-related adverse events, while the predictive role of UGT1A1 polymorphisms regarding therapeutic outcome is controversial. In this review, we will evaluate the impact of UGT1A1 genotypes on irinotecan-induced toxicity and therapeutic efficacy in colorectal cancer patients receiving irinotecan-based treatment.

Sign in / Sign up

Export Citation Format

Share Document